Juvenile idiopathic arthritis - change of treatment after resolution of critical shortage of tocilizumab authority application form (PB323)

Use this form to apply for change of treatment from PBS-subsidised adalimumab or etanercept to tocilizumab after resolution of critical shortage of tocilizumab for patients with juvenile idiopathic arthritis.

Page last updated: 17 November 2022.
QC 55884